Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Mar 19;121(12):e2402533121.
doi: 10.1073/pnas.2402533121. Epub 2024 Mar 11.

Improving T cell killing and understanding senescence: Possible roles for TP53 in cancer immunotherapy

Arnold J Levine  1
Affiliations
Comment

Improving T cell killing and understanding senescence: Possible roles for TP53 in cancer immunotherapy

Arnold J Levine. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests statement:A.J.L. is a consultant for Chugai Pharmaceutical company. He is a founder, board member and consultant at PMV Pharma, which produces small molecules that reactivate p53 mutant proteins and produce wild type proteins. He is a board member of GeneCentric a cancer RNA diagnostic company. And he consults for ROME (autoimmunity), and WCG (an IRB company).

Comment on

References

    1. Roselle C., et al. , Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α. Proc. Natl. Acad. Natl. Sci. U.S.A. 121, e2317735121 (2024). - PMC - PubMed
    1. Levine A. J., p53: 800 million years of evolution and 40 years of discovery. Nat. Rev. Cancer 20, 471–480 (2020), 10.1038/s41568-020-0262-1. - DOI - PubMed
    1. Khoury M. P., Bourdon J. C., The isoforms of the p53 protein. Cold Spring Harb. Perspect. Biol. 2, a000927 (2010), 10.1101/cshperspect.a000927. - DOI - PMC - PubMed
    1. Levine A. J., P53 and the immune response: 40 years of Exploration—a plan for the future. Review in special issue "p53 in Cancer and beyond-40 Years after Its Discovery". Guest Editors: Candeias M., Marco M., Ohki R., Int. J. Mol. Sci. 21, pii: E541 (2020), 10.3390/ijms21020541, PMCID: PMC7013403 PMID: 31952115. - DOI - PMC - PubMed
    1. Horikawa I., Harris C. C., Δ133p53: A p53 isoform enriched in human pluripotent stem cells. Cell Cycle 16, 1631–1632 (2017). - PMC - PubMed

Substances